Medikamentöse Therapie:
TNF-Blocker
TNF-Blocker Präparatewahl
Tocilizumab
Leflunomid
Rituximab
Abatacept
NSAR
Opioid-Analgetika
Mycophenolsäure
Immunglobuline
Anakinra
Wirkstoffe
Einsatz
Rilonacept und Canakinumab
Literatur



Lokaltherapie:
Topika
Radiosynoviorthese



Therapie bei:
Impfungen
Schwangerschaft
Kinder- und Jugendrheuma
Sjögren-Syndrom
Pulmonaler Hypertonie
Raynaud-Syndrom
Lyme Borreliose



Sonstige Stellungnahmen



IV. Literatur

  1. Manger B (2002) Empfehlungen der Deutschen Gesellschaft für Rheumatologie zur Therapie der rheumatoiden Arthritis mit dem IL-1-Rezeptorantagonisten Anakinra (KineretR). Z Rheumatol 61(6): 698-700.

  2. Bresnihan B (2001) The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 30(5 Suppl 2): 17-20.

  3. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41(12): 2196-2204.

  4. Cohen S, Hurd E, Cush J, et al. (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(3): 614-624.

  5. Bresnihan B, Newmark R, Robbins S, Genant HK (2004) Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol 31(6): 1103-1111.

  6. Jiang Y, Genant HK, Watt I, et al. (2000) A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 43(5): 1001-1009.

  7. Furst DE, Keystone EC, Kirkham B, et al. (2008) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67 Suppl 3: iii2-25.

  8. Mertens M, Singh JA (2009) Anakinra for Rheumatoid Arthritis: A Systematic Review. J Rheumatol 36(6): 1118-1125.

  9. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA (2005) Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 52(6): 1794-1803.

  10. Vasques Godinho FM, Parreira Santos MJ, Canas da SJ (2005) Refractory adult onset Still's disease successfully treated with anakinra. Ann Rheum Dis 64(4): 647-648.

  11. Lequerre T, Quartier P, Rosellini D, et al. (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67(3): 302-308.

  12. Manger B (2008) Der adulte Morbus Still. Z Rheumatol 67(5): 415-422.

  13. Guignard S, Dien G, Dougados M (2007) Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol 25(5): 758-759.

  14. Ruiz PJ, Masliah E, Doherty TA, Quach A, Firestein GS (2007) Cardiac death in a patient with adult-onset Still's disease treated with the interleukin 1 receptor inhibitor anakinra. Ann Rheum Dis 66(3): 422-423.

  15. Efthimiou P, Paik PK, Bielory L (2006) Diagnosis and management of adult onset Still's disease. Ann Rheum Dis 65(5): 564-572.

  16. Quartier P, Allantaz F, Cimaz R, et al. (2008) Efficacy, safety and effect on gene expression profiling of anakinra in systemic-onset juvenile idiopathic arthritis: final results of a randomised, placebo-controlled trial (ANAJIS). Pediatric Rheumatology 6 (Suppl I): P27.

  17. Gattorno M, Piccini A, Lasiglie D, et al. (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58(5): 1505-1515.

  18. Ohlsson V, Baildam E, Foster H, et al. (2008) Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) 47(4): 555-556.

  19. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201(9): 1479-1486.

  20. Guellac N, Niehues T (2008) Interdisziplinäre S2-Leitlinie der juvenilen idiopathischen Arthritis. Klin Pädiatr 220(6): 392-402.

  21. Horneff G (2009) Die medikamentöse Therapie der juvenilen idiopathischen Arthritis bei Kindern. Arthritis + Rheuma 29(2): 81-93.

  22. Aksentijevich I, Masters SL, Ferguson PJ, et al. (2009) An Autoinflammatory Disease with Deficiency of the Interleukin-1-Receptor Antagonist. N Engl J Med 360(23): 2426-2437.

  23. Prieur AM, Griscelli C, Lampert F, et al. (1987) A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl 66: 57-68.

  24. Brydges S, Kastner DL (2006) The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr Top Microbiol Immunol 305: 127-160.

  25. Stojanov S, Kastner DL (2005) Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 17(5): 586-599.

  26. Ben-Chetrit E, Levy M (1998) Colchicine: 1998 update. Semin Arthritis Rheum 28(1): 48-59.

  27. Goldfinger SE (1972) Colchicine for familial Mediterranean fever. N Engl J Med 287(25): 1302.

  28. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF (2004) Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 50(2): 607-612.

  29. Dybowski F, Jakobs B, Altmeyer P, Braun J (2006) Erfolgreiche Behandlung der klinischen Manifestationen des Muckle-Wells-Syndroms mit Anakinra. Dtsch Med Wochenschr 131(34-35): 1863-1866.

  30. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355(6): 581-592.

  31. Lovell DJ, Bowyer SL, Solinger AM (2005) Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 52(4): 1283-1286.

  32. Mirault T, Launay D, Cuisset L, et al. (2006) Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum 54(5): 1697-1700.

  33. O'Connell SM, O'Regan GM, Bolger T, et al. (2007) Response to IL-1-receptor antagonist in a child with familial cold autoinflammatory syndrome. Pediatr Dermatol 24(1): 85-89.

  34. Rynne M, Maclean C, Bybee A, McDermott MF, Emery P (2006) Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism. Ann Rheum Dis 65(4): 533-534.

  35. Yamazaki T, Masumoto J, Agematsu K, et al. (2008) Anakinra improves sensory deafness in a Japanese patient with Muckle-Wells syndrome, possibly by inhibiting the cryopyrin inflammasome. Arthritis Rheum 58(3): 864-868.

  36. Leslie KS, Lachmann HJ, Bruning E, et al. (2006) Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 142(12): 1591-1597.

  37. Belkhir R, Moulonguet-Doleris L, Hachulla E, Prinseau J, Baglin A, Hanslik T (2007) Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 146(11): 825-826.

  38. Cailliez M, Garaix F, Rousset-Rouviere C, et al. (2006) Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J Inherit Metab Dis 29(6): 763.

  39. Calligaris L, Marchetti F, Tommasini A, Ventura A (2008) The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 167(6): 695-696.

  40. Gattorno M, Pelagatti MA, Meini A, et al. (2008) Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 58(5): 1516-1520.

  41. Gattringer R, Lagler H, Gattringer KB, et al. (2007) Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Invest 37(11): 912-914.

  42. Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ (2007) Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 66(11): 1545-1546.

  43. Rigante D, Ansuini V, Bertoni B, et al. (2006) Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol Int 27(1): 97-100.

  44. Gerard S, le GB, Maugars Y, Berthelot JM, Malard O (2007) Lasting remission of a Muckle-Wells syndrome with CIAS-1 mutation using half-dose anakinra. Joint Bone Spine 74(6): 659.

  45. Haibel H, Rudwaleit M, Listing J, Sieper J (2005) Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 64(2): 296-298.

  46. Tan AL, Marzo-Ortega H, O'Connor P, Fraser A, Emery P, McGonagle D (2004) Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 63(9): 1041-1045.

  47. Gibbs A, Gogarty M, Bresnihan B, et al. (2006) Moderate clinical response and absence of MRI or immunohistological change suggest that Anakinra is ineffective in psoriatic arthritis. 54 (Suppl.) ed.  p. S719.

  48. Jung N, Hoheisel R, Haase I, et al. (2005) Anakinra (IL-1RA) in the treatment of patients with active psoriatic arthritis refractory to or intolerant of methotrexate (MTX). 64 (Suppl.III) ed.  p. 1092.

  49. Ilowite N, Porras O, Reiff A, et al. (2009) Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 28(2): 129-137.

  50. Goldbach-Mansky R, Shroff SD, Wilson M, et al. (2008) A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 58(8): 2432-2442.

  51. Hoffman HM, Throne ML, Amar NJ, et al. (2008) Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58(8): 2443-2452.

  52. Alten R, Gram H, Joosten LA, et al. (2008) The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 10(3): R67.

  53. Hoffman HM, Wolfe F, Belomestnov P, Mellis SJ (2008) Cryopyrin-associated periodic syndromes: development of a patient-reported outcomes instrument to assess the pattern and severity of clinical disease activity. Curr Med Res Opin 24(9): 2531-2543.

  54. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. (2009) Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome. N Engl J Med 360(23): 2416-2425.

  55. Ruperto N, Quartier P, Wulffraat N, et al. (2008) A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA). Pediatric Rheumatology 6(Suppl.1): S1-S2.

  56. McGonagle D, Tan AL, Madden J, Emery P, McDermott MF (2008) Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 58(2): 631-633.

  57. So A, De ST, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9(2): R28.

  58. McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P, McDermott MF (2007) Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 66(12): 1683-1684.

  59. Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA (2008) Resistant Behcet disease responsive to anakinra. Ann Intern Med 149(4): 284-286.

  60. Vounotrypidis P, Sakellariou GT, Zisopoulos D, Berberidis C (2006) Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatology (Oxford) 45(4): 491-492.

  61. Wendling D, Govindaraju S, Prati C, Toussirot E, Bertolini E (2008) Efficacy of anakinra in a patient with refractory relapsing polychondritis. Joint Bone Spine 75(5): 622-624.

  62. de Koning HD, Bodar EJ, van der Meer JW, Simon A (2007) Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 37(3): 137-148.

  63. Schneider SW, Gaubitz M, Luger TA, Bonsmann G (2007) Prompt response of refractory Schnitzler syndrome to treatment with anakinra. J Am Acad Dermatol 56(5 Suppl): S120-S122.

  64. Thonhofer R, Uitz E, Graninger W (2007) Schnitzler's syndrome--exacerbation after anti-TNF treatment. Rheumatology (Oxford) 46(6): 1041-1042.

  65. Eiling E, Moller M, Kreiselmaier I, Brasch J, Schwarz T (2007) Schnitzler syndrome: treatment failure to rituximab but response to anakinra. J Am Acad Dermatol 57(2): 361-364.

  66. Dybowski F, Sepp N, Bergerhausen HJ, Braun J (2008) Successful use of anakinra to treat refractory Schnitzler's syndrome. Clin Exp Rheumatol 26(2): 354-357.

  67. Moosig F, Zeuner R, Renk C, Schroder JO (2004) IL-1RA in refractory systemic lupus erythematosus. Lupus 13(8): 605-606.

  68. Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M (2005) Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 64(4): 630-633.

  69. Behrens EM, Kreiger PA, Cherian S, Cron RQ (2006) Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol 33(10): 2081-2084.

Therapie-Empfehlung Anakinra

 

Druckversion (PDF)